Last reviewed · How we verify
Leiomyosarcoma
Approved treatments
- Yondelis · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Yondelis · Janssen Prods
Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth.
Pipeline
- Ontorpacept (TTI-621) · Pfizer Inc. — discontinued
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Leiomyosarcoma patent landscape — cliff calendar, originator estates, attackable patents
- Leiomyosarcoma treatment landscape brief
- Leiomyosarcoma treatment updates RSS
Frequently asked questions about Leiomyosarcoma
What drugs treat Leiomyosarcoma?
Tracked treatments include Yondelis.
What is the treatment for Leiomyosarcoma?
Standard treatment for Leiomyosarcoma includes Yondelis. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Leiomyosarcoma?
1 pipeline drugs tracked. Top candidates: Ontorpacept (TTI-621).
Related
- Treatment landscape: Leiomyosarcoma patent cliff · Leiomyosarcoma CI report
- Treatment: Yondelis · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Yondelis · Janssen Prods
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing